期刊文献+

不同浓度破骨细胞分化因子和1,25-(OH)_2D_3体外诱导大鼠破骨样细胞形成的研究 被引量:2

Induction of osteoclast-like cells using different concentrations of receptor activator of NF-κB ligand and 1,25-(OH)_2D_3
下载PDF
导出
摘要 目的研究破骨细胞分化因子和1,25-(OH)2D3共同作用对大鼠破骨样细胞体外形成的影响。方法采用大鼠脾细胞和骨细胞联合培养,实验组分别加入不同浓度的破骨细胞分化因子和1,25-(OH)2D3进行诱导,并利用抗酒石酸酸性磷酸酶(TRAP)染色、骨吸收陷窝检测等方法对破骨样细胞进行鉴定,对TRAP(+)的细胞进行计数和统计学分析。统计学方法采用单因素方差分析,组间比较用SNK检验。结果各实验组细胞均有TRAP(+)多核破骨细胞出现,并在牙本质磨片上形成吸收陷窝,破骨细胞分化因子和1,25-(OH)2D3共同作用的双因子诱导TRAP(+)多核破骨细胞形成的数量要大于使用单因子诱导,且因子浓度越大,诱导效果越好。结论破骨细胞分化因子和1,25-(OH)2D3共同作用及高浓度的因子诱导可有效诱导体外破骨样细胞的形成。 Objective To study the effects of receptor activator of NF-κB ligand (RANKL) and 1,25-(OH)2D3 on the formation of osteoclast-like cells in vitro. Methods The rat spleen cells and bone cells were incubated in the same compartment. The experimental group was incubated with different concentrations of RANKL and 1,25-(OH)2D3. The TRAP staining, bone absorption lacunae detection were employed to identify the osteoclast-like cells and the number of TRAP (+) cells. One-way ANOVA and SNK test were used for statistic analysis. Results TRAP (+) multi-nuclear cells, in conjunction with absorption lacunae, were observed in all groups of cells. A greater number of TRAP (+) multinuclear cells were observed in the groups treated with the combination of RANKL and 1,25-(OH)2D3, in a concentration dependent fashion. Conclusion The effects of RANKL and 1,25-(OH)2D3, in particular, at higher con-centrations, may promote the genesis and increase the absorption of osteoclasts.
出处 《中国药物与临床》 CAS 2014年第5期597-599,I0002,共4页 Chinese Remedies & Clinics
关键词 破骨细胞 细胞培养技术 骨化三醇 核因子ΚB受体活化因子配体 Osteoclasts Cell culture techniques Calcitriol Receptor activator of NF-KB ligand
  • 相关文献

参考文献3

二级参考文献18

  • 1GLANTSCHNIG H, FISHER J E, WESOLOWSKI G, et al. M-CSF, TNFa and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase [J].Cell Death and Differentiation, 2003,10: 1165-1177.
  • 2YAVROPOULOU M P, YOVOS J G. Osteoclastogenesis - Current knowledge and future perspectives[J].J Musculoskelet Neuronal Interact, 2008,8 (3) : 204-216.
  • 3BURGER E H, VAN D M. In vitro formation of osteoclasts from long-term culture of bone marrow mononuclear phagocytes[J].J Exp Med,1982,156:1604-1614.
  • 4TEITELBAUM S L. Bone resorption by osteoelasts. [J].Science, 2000,289 : 1504-1508.
  • 5KODAMA H, YAMASAKI A, NOSE M, et al. Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor [J].J Exp Med, 1991,173 : 269-272.
  • 6KONG Y Y, YOSHIDA H, SAROSI I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis[J].Nature, 1999,397 : 315-323.
  • 7BOYLE W J, SIMONET W S, LACEY D L. Osteoclast differentiation and activation[J]. Nature,2003, 423(3) :337-342.
  • 8LEE S E, CHUNG W J, KWAK H B, et al. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK[J]. J Biol Chem, 2001,276(52): 49343-49349.
  • 9HAN B K, JONG Y K, KWANG J K, et al. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss[J]. Biol Pharm Bull, 2009,32(7):1193-1198.
  • 10Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev, 1992, 13( 1 ): 66 ~ 68

共引文献38

同被引文献24

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部